Steven M. Keller

6.7k total citations · 2 hit papers
102 papers, 3.7k citations indexed

About

Steven M. Keller is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Surgery. According to data from OpenAlex, Steven M. Keller has authored 102 papers receiving a total of 3.7k indexed citations (citations by other indexed papers that have themselves been cited), including 70 papers in Pulmonary and Respiratory Medicine, 35 papers in Oncology and 22 papers in Surgery. Recurrent topics in Steven M. Keller's work include Lung Cancer Diagnosis and Treatment (46 papers), Lung Cancer Treatments and Mutations (44 papers) and Cancer Immunotherapy and Biomarkers (12 papers). Steven M. Keller is often cited by papers focused on Lung Cancer Diagnosis and Treatment (46 papers), Lung Cancer Treatments and Mutations (44 papers) and Cancer Immunotherapy and Biomarkers (12 papers). Steven M. Keller collaborates with scholars based in United States, South Korea and Spain. Steven M. Keller's co-authors include David H. Johnson, Sudeshna Adak, Henry Wagner, Robert B. Livingston, Corey J. Langer, Walter J. Curran, Michael C. Perry, Arnold Herskovic, Wyatt C. Fowler and Ritsuko Komaki and has published in prestigious journals such as New England Journal of Medicine, Journal of the American Chemical Society and Journal of Clinical Oncology.

In The Last Decade

Steven M. Keller

99 papers receiving 3.6k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Perioperative Pembrolizumab for Early-Stage Non–Small-Cell Lung Cancer

2023 460 citations Heather A. Wakelee, Moïshe Liberman et al. profile →
Pembrolizumab Plus Concurrent Chemoradiation Therapy in Patients With Unresectable, Locally Advanced, Stage III Non–Small Cell Lung Cancer

2021 162 citations Ayman Samkari, Steven M. Keller et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Steven M. Keller United States	31	2.5k	1.5k	596	569	398	102	3.7k
Brian C. McCaughan Australia	37	2.8k 1.1×	1.2k 0.8×	818 1.4×	851 1.5×	467 1.2×	121	4.5k
Roldano Fossati Italy	18	1.7k 0.7×	1.7k 1.1×	418 0.7×	367 0.6×	304 0.8×	49	3.5k
Gary M. Strauss United States	31	4.5k 1.8×	1.8k 1.2×	398 0.7×	473 0.8×	1.0k 2.6×	103	5.4k
Tawee Tanvetyanon United States	32	1.3k 0.5×	1.7k 1.1×	724 1.2×	721 1.3×	288 0.7×	135	3.3k
Gavin Wright Australia	27	2.1k 0.8×	1.3k 0.8×	380 0.6×	463 0.8×	402 1.0×	128	3.0k
Roger R. Connelly United States	35	1.6k 0.6×	1.1k 0.7×	551 0.9×	776 1.4×	253 0.6×	73	3.8k
Jean Trédaniel France	26	974 0.4×	1.2k 0.8×	428 0.7×	565 1.0×	288 0.7×	109	2.6k
Yukinori Sakao Japan	30	2.2k 0.9×	1.2k 0.8×	483 0.8×	483 0.8×	371 0.9×	180	3.0k
James T. Symanowski United States	28	3.1k 1.2×	1.4k 0.9×	415 0.7×	680 1.2×	484 1.2×	172	4.8k
Raymond P. Abratt South Africa	24	1.4k 0.6×	1.3k 0.9×	370 0.6×	448 0.8×	245 0.6×	81	2.4k

Countries citing papers authored by Steven M. Keller

Since Specialization

Citations

This map shows the geographic impact of Steven M. Keller's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Steven M. Keller with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Steven M. Keller more than expected).

Fields of papers citing papers by Steven M. Keller

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Steven M. Keller. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Steven M. Keller. The network helps show where Steven M. Keller may publish in the future.

Co-authorship network of co-authors of Steven M. Keller

This figure shows the co-authorship network connecting the top 25 collaborators of Steven M. Keller. A scholar is included among the top collaborators of Steven M. Keller based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Steven M. Keller. Steven M. Keller is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Garassino, Marina Chiara, Heather A. Wakelee, Jonathan Spicer, et al.. (2024). Health-related quality of life (HRQoL) outcomes from the randomized, double-blind phase 3 KEYNOTE-671 study of perioperative pembrolizumab for early-stage non-small-cell lung cancer (NSCLC).. Journal of Clinical Oncology. 42(16_suppl). 8012–8012. 2 indexed citations

Wakelee, Heather A., Moïshe Liberman, Terufumi Kato, et al.. (2023). KEYNOTE-671: Randomized, double-blind, phase 3 study of pembrolizumab or placebo plus platinum-based chemotherapy followed by resection and pembrolizumab or placebo for early stage NSCLC.. Journal of Clinical Oncology. 41(17_suppl). LBA100–LBA100. 11 indexed citations

Steuer, Conor, Opeyemi A. Jegede, Suzanne E. Dahlberg, et al.. (2021). Smoking Behavior in Patients With Early-Stage NSCLC: A Report From ECOG-ACRIN 1505 Trial. Journal of Thoracic Oncology. 16(6). 960–967. 8 indexed citations

Borghaei, Hossein, Corey J. Langer, Shirish M. Gadgeel, et al.. (2018). 24-Month Overall Survival from KEYNOTE-021 Cohort G: Pemetrexed and Carboplatin with or without Pembrolizumab as First-Line Therapy for Advanced Nonsquamous Non–Small Cell Lung Cancer. Journal of Thoracic Oncology. 14(1). 124–129. 169 indexed citations

Mullapudi, Nandita, Bin Ye, Masako Suzuki, et al.. (2015). Genome Wide Methylome Alterations in Lung Cancer. PLoS ONE. 10(12). e0143826–e0143826. 27 indexed citations

Lin, Jenny J., Melanie M. Wall, Andrew Berman, et al.. (2014). Association of Patient–Provider Communication Domains with Lung Cancer Treatment. Journal of Thoracic Oncology. 9(9). 1249–1254. 18 indexed citations

Lin, Jenny J., Grace Mhango, Melanie M. Wall, et al.. (2014). Cultural Factors Associated with Racial Disparities in Lung Cancer Care. Annals of the American Thoracic Society. 11(4). 489–495. 74 indexed citations

Harris, Thomas M., Qiulu Pan, Juan Sironi, et al.. (2010). Both Gene Amplification and Allelic Loss Occur at 14q13.3 in Lung Cancer. Clinical Cancer Research. 17(4). 690–699. 38 indexed citations

Keller, Steven M., et al.. (2008). Intraoperative Staging and Surgical Management of Stage IIIA/N2 Non–Small Cell Lung Cancer. Thoracic surgery clinics/Thorac. surg. clin.. 18(4). 381–391. 3 indexed citations

10.

Yang, Chia‐Ping Huang, Lluís López-Barcons, Steven M. Keller, et al.. (2007). Targeting Protein Translation in Human Non–Small Cell Lung Cancer via Combined MEK and Mammalian Target of Rapamycin Suppression. Cancer Research. 67(23). 11300–11308. 66 indexed citations

11.

Costa, Daniel B., Sigui Li, Olivier Kocher, et al.. (2007). Immunohistochemical analysis of C/EBPα in non-small cell lung cancer reveals frequent down-regulation in stage II and IIIA tumors: A correlative study of E3590. Lung Cancer. 56(1). 97–103. 17 indexed citations

12.

Dubey, Sarita, Patricia Stephenson, Donna E. Levy, et al.. (2006). EGFR Dinucleotide Repeat Polymorphism as a Prognostic Indicator in Non-small Cell Lung Cancer. Journal of Thoracic Oncology. 1(5). 406–412. 32 indexed citations

13.

McDaid, Hayley M., Lluís López-Barcons, Aaron Grossman, et al.. (2005). Enhancement of the Therapeutic Efficacy of Taxol by the Mitogen-Activated Protein Kinase Kinase Inhibitor CI-1040 in Nude Mice Bearing Human Heterotransplants. Cancer Research. 65(7). 2854–2860. 72 indexed citations

14.

Wakelee, Heather A., Patricia Stephenson, Steven M. Keller, et al.. (2005). Post-operative radiotherapy (PORT) or chemoradiotherapy (CPORT) following resection of stages II and IIIA non-small cell lung cancer (NSCLC) does not increase the expected risk of death from intercurrent disease (DID) in Eastern Cooperative Oncology Group (ECOG) trial E3590. Lung Cancer. 48(3). 389–397. 42 indexed citations

15.

Keller, Steven M., Márk Vangel, Henry Wagner, et al.. (2004). Prolonged survival in patients with resected non–small cell lung cancer and single-level N2 disease. Journal of Thoracic and Cardiovascular Surgery. 128(1). 130–137. 72 indexed citations

16.

Keller, Steven M.. (2000). Adjuvant therapy of resected non–small-cell lung cancer. Current Opinion in Oncology. 12(2). 149–155. 5 indexed citations

17.

Keller, Steven M., et al.. (1993). Epidural Narcotic Analgesia After Thoracotomy. Southern Medical Journal. 86(10). 1106–1109. 2 indexed citations

18.

Siegfried, Jill M., Jay D. Hunt, Jianyuan Zhou, Steven M. Keller, & Joseph R. Testa. (1993). Cytogenetic abnormalities in non‐small cell lung carcinoma: Similarity of findings in conventional and feeder cell layer cultures. Genes Chromosomes and Cancer. 6(1). 30–38. 6 indexed citations

19.

Kowalyshyn, Michael J., et al.. (1992). Intrathoracic organ injury associated with photodynamic therapy. Journal of Thoracic and Cardiovascular Surgery. 103(6). 1218–1223. 21 indexed citations

20.

Carp, Ned Z., et al.. (1992). DNA content in correlation with postsurgical stage in non-small cell lung cancer. The Annals of Thoracic Surgery. 53(4). 680–683. 25 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact